Andreas Emmenegger founded PIQUR Therapeutics AG and Targimmune Therapeutics AG. Currently, Mr. Emmenegger is Chief Financial Officer of Molecular Partners AG, Member-Management Board at Molecular Partners, Inc. (a subsidiary of Molecular Partners AG) and Co-Owner at Targimmune Therapeutics AG. Andreas Emmenegger is also on the board of Luzerner Kantonalbank AG and Member-Management Board at Molecular Partners, Inc.
Mr. Emmenegger previously held the position of Chief Financial Officer of Interroll Holding AG, Chief Financial Officer at The Fantastic Co. AG, Principal at Roche & Genentech, Inc., Chief Financial Officer at Roche Glycart AG, Head-Strategic Alliance at F. Hoffmann-La Roche Ltd., Controller for Dräger Beteiligungen AG and Member-Supervisory Board at PIQUR Therapeutics AG.
He received an MBA and an undergraduate degree from Instituto de Estudios Superiores de la Empresa and an undergraduate degree from Lucerne University of Applied Sciences & Arts.